Privacy preferences
Inderes uses cookies to provide a better user experience and a personalised service. By consenting to the use of cookies, we can develop an even better service and will be able to provide content that is interesting to you.
  • Forum
  • Premium
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Morning ReviewDaily market recap and key overnight highlights
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • PortfolioInderes model portfolio
    • FemmeBreaking barriers and building confidence in investing
  • Learn about investing
    • Analysis SchoolLearn how to read and understand stock analysis
    • Investing SchoolGuides and lessons to grow your investing knowledge
    • Portfolio buildersInvesting knowledge for every level, from first steps to advanced portfolio strategies.
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
    • Earnings SeasonCompare EPS estimates to reported results
    • Insider TransactionsTrack buying and selling activity by company insiders
    • Short SellingSee which listed companies have disclosed short interest
    • Virtual Analyst ChatAsk questions and get instant AI-powered investment insights
    • Compound Interest CalculatorSee how your savings grow with the power of compound interest.
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • Instagram
  • X (Twitter)
  • Tiktok
  • Linkedin
Get in touch
  • info@inderes.fi
  • +358 10 219 4690
  • Porkkalankatu 5
    00180 Helsinki
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Q&A
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

Transcripts

Read transcripts of webcasts and audiocasts

Transcripts

Read transcripts of webcasts and audiocasts

All regions
Finland
Sweden
Denmark
Norway
Latest
Trending
Followed

Oncopeptides, Audiocast, Q2'26

By Inderes8/27/2026, 7:00 AM
Oncopeptides

Disclaimer: This is a machine-generated transcript and may contain inaccuracies.

Sofia Heigis
00:00 - 02:25

Welcome to the Oncopeptides AB webcast for the second quarter of 2026. Please note the disclaimer regarding forward-looking statements. Today's presentation is led by me, Sofia Heigis, and our CFO, Henrik Bergentoft. We delivered net sales of 31.1 million SEK in Q2 2026, representing a 62% increase compared to Q2 2025. For the first half of the year, net sales reached 56.5 million, up 74% year over year. Following the rights issue completed earlier this year, our cash position stood at 158 million SEK at the end of the second quarter. We remain on track towards reaching positive cash flow during 2027. During the second quarter, we achieved several critical commercial, clinical, and regulatory milestones, which demonstrates that even though our organization is lean, Oncopeptides AB consists of people with a high level of competence, motivation, and drive. We submitted our Type II variation application to the EMA to expand the Pepaxti label into third-line multiple myeloma patients. Preclinical data for our novel NK cell engager was presented at the AACR Annual Meeting. We presented five scientific abstracts and hosted a well-attended PDC symposium at the EHA Congress right here in Stockholm. The first patient was enrolled in our non-interventional real-world evidence study, Marina. Outside of multiple myeloma, we received regulatory approval from Norwegian authorities and enrolled the first patient in our glioblastoma window-of-opportunity study. We signed a distribution agreement with Salus Group covering 11 countries across Central and Eastern Europe. And lastly, after the period, we achieved our first CEE expansion milestone by securing a list price for Pepaxti in Slovenia. Now over to Henrik for a walkthrough of the second quarter financials.

Henrik Bergentoft
02:26 - 05:16

Thank you, Sofia. So let me start with the operating momentum. Net sales reached 31.1 million in the quarter, up 62% year on year, while first half sales increased 74% to 56.5 million. The 98% gross margin for the first half shows that this growth converts efficiently into gross profit and reinforces the scalability of our business model. We are powering that momentum with disciplined cost management. First half operating expenses decreased 2% to 146.9 million. Combined with the sales growth, this helped improve the EBIT loss to 86.2 million from 116.1 million. The key message is that the business is moving in the right direction, with sales uptake, strong margins, and tight cost control. We are not buying growth at any price. We are scaling revenue while constantly monitoring the quality of every krona spent. Our approach to cost is very selective and execution-led. Quarterly operating expenses were 81.1 million, with commercial investments focused on the European markets already generating growth in Germany, Spain, and Italy. Sales and marketing spend of 40.8 million therefore supports a clear revenue objective. At the same time, G&A costs decreased to 16.7 million from 18.6 million, demonstrating tangible cost control. R&D was 23.5 million SEK in the quarter, with efforts now focused on advancing our pipeline into the clinic. With the glioblastoma window-of-opportunity study, we have made progress across the first half. Total operating expenses were down 2% year-on-year. As communicated, the second quarter cost base is higher than the first quarter, mainly due to additional Congresses. All in all, our cost base is to be perceived as disciplined allocation to protect commercial momentum, control overhead costs, and preserve the programs with the strongest potential, spending our funds to grow revenue today and build high-value options for tomorrow. We ended the quarter with 158 million SEK in cash. The rights issue, completed in March, contributed 167 million SEK after transaction costs, materially strengthening the liquidity position and providing a firmer financial base for execution towards a positive cash flow during 2027. And with that, over to you again, Sofia.

Sofia Heigis
05:17 - 20:24

Thank you. Henrik, the foundation of Oncopeptides AB is built on our commercial execution in Europe, targeting an estimated 1.5 billion SEK market potential under our current label. In parallel, we are unlocking additional geographic markets through commercial partnerships. Long-term, our PDC platform can unlock multiple indication potential in difficult-to-treat cancers, headlined by our CNS tumor program with initial focus on glioblastoma. Addressing a global market expected to grow to 8 billion USD based on the high unmet need. Our execution during the second quarter has advanced every key pillar of this investment thesis. Commercial momentum delivered 62% revenue growth in Q2 compared to the same period last year. We formally submitted our Type II variation to enter the third-line of multiple myeloma. The glioblastoma window-of-opportunity study was initiated and the first patient was dosed. We expanded our European reach via the Salus distribution partnership in Central and Eastern Europe, while continuing active business development discussions in Japan and other regions. Turning to our commercial performance across Europe, the contribution during the quarter comes from Germany, strong uptake in Italy, and the level-up in Spain. More than 1,000 patients have now been treated with Pepaxti across Europe since our EMA approval. This growing real-world clinical experience is generating peer-to-peer advocacy and validation. Furthermore, our 1B recommendation in the EMA guidelines continues to play an important role in defining Pepaxti's unique clinical position in a complex treatment landscape. In a rapidly evolving market with many options being launched, it is critical to identify a unique position supported by both real-world data and experience. For Pepaxti, data consistently points to three distinct patient profiles where Pepaxti delivers clear value. First, for patients unable to receive immunotherapy due to, for example, frailty, advanced age, comorbidities, or concerns about the risk for severe infections, Pepaxti serves as an ideal bridge between immune-based therapies. It offers a non-cross-resistant disease control while allowing the immune system and the T cells to recover as an effective post-immunotherapy option. Salvage options for patients who have relapsed or become refractory to almost all other drugs, including BCMA-targeted agents and CAR-T cell therapies. During EHA in Stockholm in June, we hosted a symposium titled "Beyond Immunotherapy," exploring the treatment class of PDC and clinical realities, shared by Professor Maria Krauth and featuring six leading hematologists from Germany, Spain, and Italy; the symposium addressed sequencing strategies and highlighted how Pepaxti's unique PDC mechanism offers an outpatient-friendly solution that does not rely on host immune fitness. I was, of course, attending myself, and I enjoyed meeting and listening to all the experts sharing their views and experience. Seven slightly different perspectives based on the country and the setting they came from, all confirming the unmet need and the use of Pepaxti in the positions in which we believe we can make the most difference for patients. True external validation. In addition to the symposium, we had a Swedish-themed booth. We launched digital engagement campaigns throughout EHA, and we had a high number of qualitative face-to-face interactions with healthcare professionals, mainly from our key markets, but also from other markets across the globe. These activities reinforce our core messaging around the importance for patients to gain access to Pepaxti as they need therapy options, complementing immunotherapy. Today, we have several collaborations with key experts underway based on the congress activities. In Germany, commercial momentum stepped up during the quarter with steady gains in monthly new patient starts and an expanding prescriber base across university hospitals and office-based practices. We also enrolled the first patient into the prospective MARINA RWE study, strengthening our office-based data generation with strict cost control and volume growth. Germany is progressing towards country-level profitability for the full year. We should be honest and say that it is only the experienced prescribers that use Pepaxti in the exact right position and in fourth-line in Germany. This means that once physicians gain experience, they gain confidence and move from very late lines to the right position. It also means we still have work to do to ensure we get more use in earlier lines, which commonly means even longer treatment duration. In short, there is still a lot of potential to capture in Germany. The German Pepaxti prescriber base continues to demonstrate steady growth with a high number of multiple myeloma prescribers in Germany. We still have many more left to gain. Our focus is naturally unlocking sites with the highest potential. Italy continues to perform exceptionally well and remains a key growth driver. It represents our most mature market in terms of prescriber experience and fourth-line usage, showing the highest estimated average number of treatment cycles per patient. We are seeing a continuous broadening of the hospital accounts throughout the country. In Spain, we have worked hard to actively manage the local dynamics in a very stressed market. Spain has not only experienced many launches in a very short period, but also unusual limitations in access to HCPs due to the strike that has been ongoing during the full period. We are starting to see the results of our resilience and all our efforts, with a clear step up in commercial uptake and Q2 achieving an all-time high monthly sales level in June. We are continuing to work closely with key opinion leaders, as peer-to-peer recommendations are key in a pressured market to sustain this positive momentum. Our phased rollout across Europe covers an estimated 1.5 billion SEK market potential under the current label, protected by market exclusivity until 2037. We have direct commercial operations established in the phase one and part of our phase two markets. A recent agreement with Salus accelerates entry into Central and Eastern Europe, and I will get back to CEE in a short while. But first, let's focus on a brief update on where we stand with the Type II variation submitted to the EMA. Our submission to move from fourth-line into third-line treatment represents a transformative opportunity. It can shift our indication from adult patients that are refractory to a proteasome inhibitor, IMiD, and anti-CD38 monoclonal antibody, to patients with at least two prior lines of therapy and who are only refractory to lenalidomide in their last line of therapy. Moving one line up and removing the triple-class refractory requirement allows clinicians to identify and treat patients earlier. Expanding into third-line therapy acts as a commercial and clinical multiplier, coming with the opportunity to double the target patient population in Europe. In addition, the potential to double average treatment duration is based on the phase three OCEAN data. Important to note is that the established German basket model supports innovative pricing and, maybe most important. We do fulfill an unmet need with a mode of action complementary to other therapies. Following our submission between May and July, we expect a CHMP opinion sometime between September and November. In case of a positive opinion, that can lead to an EC decision, which will come plus 30 to 60 days after a potential positive opinion. Timing on the CHMP opinion will depend on the complexity and extent of feedback from the EMA. Should we gain this approval, we will submit reimbursement dossiers in our key markets as soon as administratively possible after the approval. In Germany, a company can, according to local rules, start to sell on a new indication right after the reimbursement dossier has been submitted. In Italy and Spain, a price needs to be concluded for the new indication before off-label sales to third-line patients is possible. We will, of course, keep you updated on the progress. Our partnership strategy allows us to scale globally and capital-efficiently. The agreement, announced during Q2, covers 11 key countries, representing an estimated addressable market with 150 million SEK potential under the current label. Just like we did a launch sequence across Europe, Salus has assessed and made a launch sequence across CEE, where Slovenia was first on that list. It is a small market, but most important from a pricing perspective, to achieve a list price in Slovenia already now in August; this confirms that Salus is a partner with the right competence and drive, and sales in Slovenia can start once a price negotiation is concluded. Regarding the launch sequence in CEE, Croatia and the Czech Republic are next up. In parallel with our current partnerships, we remain very engaged in active partnership discussions in Japan and in other territories. Our pipeline leverages our proprietary PDC and SPiKE platforms. Key assets include OPD5, currently focused on glioblastoma. OPDC3, designed for enhanced selectivity in solid tumors, and OPSP1 are novel natural killer cell engagers. The first major obstacle in brain cancer is crossing the blood-brain barrier. Based on pre-clinical data, we believe we can overcome this barrier. This, however, needs to be confirmed in the clinic, and through our 10-patient window-of-opportunity study at Oslo University Hospital, we are using an approved PDC probe to rapidly demonstrate human brain tumor penetration in a cost-efficient manner, aiming to generate the clinical validation needed for us to take the next step. We enrolled the first patient into the study during Q2. The first step to allow further recruitment of patients was an assessment by the Safety Review Committee. This is completed, and recruitment of additional patients has been initiated. We will keep you posted on the progress. To put our glioblastoma opportunity into perspective, the current standard of care drug, temozolomide, is an alkylating agent. This means alkylators are today considered to be the most effective drug class to use in glioblastoma patients. Glioblastoma is a sturdy and cold tumor, and so far, for example, immunotherapy has been very difficult to get to work. Despite the treatment with temozolomide, the prognosis is poor and the unmet need is high, mainly due to three additional barriers, including poor delivery. Only around 30% of the drug crosses the blood-brain barrier and reaches the brain. It has limited potency. It has relatively low cancer-killing power. This is partly due to the last barrier, which is high and rapid resistance development. The tumor cells quickly adapt and learn to repair the damage that temozolomide causes. In fact, 60% of patients already have a mutation at diagnosis that supports the tumor in its repair process. The treatment targets single-stranded DNA damage within the nucleus. All glioblastoma patients need new treatment options, but these patients do have a high need already in the first line. Our PDCs kill through alkylation, but are engineered to overcome all three challenges; in preclinical testing, they demonstrate 100% blood-brain barrier penetration in vitro and in vivo. Trials demonstrate high glioblastoma cytotoxicity that seems to be independent of the most common mutation for DNA repair. We believe this is due to the high blood-brain barrier penetration in combination with the dual mechanism of action, which damages DNA double strands in the nucleus and in the mitochondria, allowing the PDCs to overcome resistance development. This makes our PDC a uniquely differentiated alkylating drug candidate designed to overcome the most common barriers and treat hard-to-reach aggressive brain tumors where other therapies fall short. If we succeed, we have the opportunity to make a huge difference for patients. Which makes me excited about this program. To summarize, Q2 2026 has been marked by strong execution across all fronts. We recorded 62% revenue growth in Q2 compared to the same period last year. A strengthened cash position supporting our pathway to 2027. Cash flow positivity. Regulatory submission to the EMA with the purpose to potentially double the number of addressable patients and increase treatment duration. Strategic partnership expansion across 11 key markets and clinical progress in glioblastoma. Targeting a disease with a very high unmet medical need and a growing global market potential. Thank you for your time and we will now open the line for questions.

Operator
20:25 - 20:42

If you wish to ask a question, please dial star five on your telephone keypad to enter the queue. If you wish to withdraw your question, please dial pound key six on your telephone keypad. The next question comes from Richard Romanus from Redeye. Please go ahead.

Richard Romanus
20:44 - 20:56

Good morning. First question is about the sales situation in Spain. How do you see that working out over the next part of this year.

Sofia Heigis
20:57 - 22:10

Good morning, Richard. As I said during the call, we did see a level up in Spain towards the end of the quarter. It is uncertain, to be honest, about access in the second half of the year because there is no clarity on if they will start to strike again. What we do know is that there is no resolution to the issue in terms of HCP availability during summer. That has been tough if you read it in the media, etc. Our tactic has been to engage the top experts to ensure that even though we do not have the same access, and even though the competition is fierce, they always recommend Pepaxti in the right position. We have been working very hard and have had several initiatives and projects running together with all the top KOLs in Spain, and I believe that is what we are starting to see an impact of at the end of Q2. And we will obviously continue, as I said, with these collaborations and these projects, to ensure that we maintain the momentum we have.

Richard Romanus
22:13 - 22:23

Okay. And then I was wondering about the collaboration with Salus Group. When do you think that can start to generate revenue?

Sofia Heigis
22:25 - 23:07

Yeah. So as I said, the first milestone is to get the list price in Slovenia because Slovenia is referencing Germany. And that means that the full pricing of SI will look at the German or the Slovenian list price. But when it comes to the launch sequence, even though Slovenia is a small market, that is also the first market where we negotiate price or where Salus will negotiate price. And that process is ongoing now. It is always tricky to know exactly how it runs because price negotiations can be unpredictable. But I think it's fair to say that first sales should come sometime in 2027.

Richard Romanus
23:10 - 23:31

Okay. Then a final question about finances, more specifically operating costs, which came in above what I saw in the graph. So, should we expect them to decline a bit towards trend in the next quarters this year?

Henrik Bergentoft
23:33 - 24:20

Yes. Good morning and thank you for that question. So, what we have communicated earlier is that we expect the full year operating expenses to be in the vicinity of what we had for 2025, i.e. Around 300 million SEK. Now. The split between the quarters varies a little bit, where typically Q2 and Q4 are more heavily weighted towards costs due to congresses. So, mark that full-year expense guidance from us and also note how you can expect the quarters to vary, which also means that, yes, we expect Q3 to be slightly lower than Q2.

Richard Romanus
24:22 - 24:24

Great. Thanks for answering my questions.

Sofia Heigis
24:25 - 24:26

Thank you so much.

Operator
24:27 - 24:45

As a reminder, if you wish to ask a question, please dial the pound key on your telephone keypad. There are no more phone questions at this time. So I hand the conference back to the speakers for any written questions and closing comments.

Unknown 1
24:46 - 24:51

There are a few written questions. The first one is for Sofia. Maybe elaborate a bit on the status in Japan.

Sofia Heigis
24:52 - 25:53

Yes. So, thank you for that question. When it comes to Japan, we have previously communicated that we had one specific partner to whom we gave exclusivity. We went to Japan earlier this year. We discussed with them, but we also opened up discussions with other partners because we believe there have been way too many delays in the process. Even though the partner we had selected for exclusivity still has an interest. We see further delays based on their organization and what is going on in their company, basically. So as that is out of our control, we have initiated new discussions in parallel, and we have several companies that we are currently discussing with. In fact, we are going back to Japan this fall to meet with them and others, and also continue to engage the KOLs, which is important work that is running in parallel with the partnership discussions.

Unknown 1
25:54 - 26:04

Okay. Question on cash flow positivity: can you specify when in 2027 you expect positive cash flow as communicated?

Henrik Bergentoft
26:05 - 26:38

Well, thank you for that question. The short answer is that we are reiterating our previous guidance that it will be during 2027. And of course, that is related to the fact that it is difficult to predict exactly how fast sales are going to grow and when that is going to happen. So we remain on that statement that it is due in 2027. We expect sales to cover operating expenses, hence having a cash flow positive business.

Unknown 1
26:39 - 26:45

Thank you. Greece was mentioned during our last report. What is the status there now in Q2?

Sofia Heigis
26:45 - 28:00

Yeah. So as I mentioned, the contribution in the second quarter actually only came from our key markets. Putting the growth into perspective, as we did have some catch-up in Q1 from Q4. And I would like to come back to the type of sales we have in Greece. It is an authority ordering, and they are highly dependent on, of course, the identification of patients. And the patient identification is, according to our partner, running smoothly. I mean, Greece is a small market and we are capturing almost all the patients that we can capture as of now. But the authorities have different budget constraints. So we, of course, expected to get some orders in Q2, but they had budget restrictions and reshuffled the stock across the country, which meant that Greece actually did not contribute at all in Q2. Of course, putting the growth into perspective, it only comes from our key markets, which I see as a strength in a way.

Unknown 1
28:02 - 28:06

Shifting focus to the US. Is that not a focus anymore at the moment?

Sofia Heigis
28:07 - 29:03

So currently we are not focusing on the US market. So, maybe a bit of history here. We did have a quite lengthy process where we were in discussions with the FDA. At the end of the day, they concluded to withdraw the accelerated approval. Based on that, we had a different target population than we got approved in the EMA and the target population that the OCEAN study confirmed. So for now, what we have been doing is exploring partnerships in the US. But we do not have a major focus on the US as we believe there is a quite long way to that market. And we do believe that the European commercialization is more prioritized, as well as concluding a partnership in Japan, where we do know that the regulatory authorities have quite small requirements for us to get an approval.

Unknown 1
29:06 - 29:11

Last question. Can you provide any details regarding Q3?

Sofia Heigis
29:13 - 29:44

So, I would like to refrain from commenting on the current quarter, as we always do. Q3. Ordering dynamics are always a bit strange, so even if I wanted to comment on a quarter, Q3 is not the right quarter to comment on because, due to the vacation period of both HCPs and patients and staff, the orders come in a bit unevenly during the quarter. So we will get back to that once we announce the Q3 results.

Unknown 1
29:46 - 29:51

And that concludes all the questions we had. Thank you, Sofia, and maybe some final conclusions from you.

Sofia Heigis
29:51 - 30:11

Thank you so much. So thanks to everyone that has listened in and participated today. We at Oncopeptides AB are excited about our commercial and clinical momentum, and we are really looking forward to keeping you updated on our continued progress during Q3. And with that, I wish you a nice day.

Continue to the webcast
Revenio Group Oyj, Q3'26
Language: English11/12/2026, 1:00 PM
Jukka Kainulainen Good afternoon, and welcome to the Revenio Group Corporation Q3 Earnings Call. My name is Jouni Toijala. I am the CEO. And then, again today we have Jukka Kainulainen, our CFO, on th…
Kamux, Q3'26
Language: English11/12/2026, 9:00 AM
Katerina Heterant Good morning. Welcome to the Kamux Q3 results presentation. My name is Katerina Heterant and I am Head of Investor Relations at Kamux. Today we shall go through the Q3 results presen…
Koskisen, Webcast, Q3'26
Language: Finnish11/12/2026, 8:00 AM
Jukka Pahta Hyvää huomenta ja tervetuloa tähän osavuosikatsaustilaisuuteen! Koskisen tammi–syyskuun osavuosikatsaustilaisuuteen lähdetään otsikolla: Koskisen liikevaihdon kasvu jatkui. Kohonneet kusta…
Reaktor, Q3'26
Language: Finnish11/11/2026, 9:00 AM
Pekka Horo Oikein hyvää aamupäivää kaikille ja tervetuloa tähän meidän webcastiimme. Olen Pekka Horo, Reaktorin toimitusjohtaja, ja kanssani täällä on tänään Antti Akkanen, joka aloitti lokakuussa Rea…
Savox, Q3'26
Language: English11/10/2026, 11:00 AM
Paulina Tanila Our speakers today are CEO Jerry Kettunen and CFO Juha Järvi. Jerry will give an overview of Savox as a company and go through the highlights of the quarter. After that, Juha will conti…
Raisio Oyj, Webcast, Q3'26
Language: Finnish11/10/2026, 10:00 AM
Elli Siltala Hyvää marraskuista päivää Raisiosta! Ja tervetuloa Raision tammi-syyskuun 2026 osavuosikatsauksen webcastiin! Pahoittelut pienistä teknisistä haasteista, mitä meillä oli tässä alussa. Min…
Mandatum Oyj, Audiocast, Q3'26
Language: English11/10/2026, 9:00 AM
Lotta Borgström Good morning, everyone, and welcome to the Mandatum Q3 2026 audiocast. My name is Lotta Borgström from Investor Relations. Joining me today are our CEO, Petri Niemisvirta, and our CFO,…
Solar foods Go-to-market Update
Language: English11/9/2026, 12:00 PM
Maria Hello everyone, and welcome to the Solar Foods go-to-market update. My name is Maria and I'm here today with our CEO, Rami Jokela, and CFO and Deputy CEO, Ilkka Saura. Also with us today is Heli…
Outokumpu, Webcast, Q3'26
Language: English11/6/2026, 12:30 PM
Johan Welcome to the third quarter results webcast. I am responsible for investor relations. We will start with the presentation from our CEO, Kati ter Horst, and our CFO, Marc-Simon Schaar. After the…
Endomines, Webcast, Q3'26
Language: English11/5/2026, 1:00 PM
Andy Turpin Hello, everyone, and welcome to Endomines' third-quarter results webcast. Thanks for joining us today. My name is Andy Turpin and I am the Chief Communications Officer here at Endomines. A…
Lemonsoft Oyj, Q3'26 webcast
Language: English11/5/2026, 11:00 AM
Unknown 1 Welcome to the Lemonsoft Q3 results presentation. We will start with the presentation from CEO Alpo Luostarinen, followed by the Q&A. You can send your questions throughout the event via the…
Enersense, Webcast, Q3'26
Language: English11/5/2026, 10:30 AM
Liisa Tamminen Hello and welcome to the Enersense Q3 2026 results webcast. My name is Liisa Tamminen from Enersense Investor Relations. And with me here I have our CEO, Kari Sundbäck, and CFO, Jan-Elo…
Sitowise, Q3'26
Language: English11/5/2026, 10:00 AM
Mari Reponen Good day everyone, and welcome to the Sitowise Q3 2026 results audiocast. My name is Mari Reponen, and I am responsible for strategy and IR here at Sitowise. And today with me are our act…
Orthex, Webcast, Q3'26
Language: English11/5/2026, 9:00 AM
Alexander Rosenlew Good morning and welcome to the Orthex Interim Report. My name is Alexander Rosenlew and with me I have Saara Mäkelä, CFO, and Hanna Kukkonen, our CMSO. We will take you through the…
Suominen Oyj, Q3'26
Language: English11/5/2026, 8:30 AM
Anni Luoma Good morning, everyone, and welcome to the Suominen Q3 webcast. My name is Anni Luoma. I am the Manager of External Communications and Investor Relations at Suominen. Here with me are our P…
Lumo, Webcast, Q3'26
Language: English11/5/2026, 8:00 AM
Niina Saarto Good morning, all. Welcome. This is Lumo Homes plc's third quarter result webcast. I am Niina Saarto from Treasury and Investor Relations. Today I have two gentlemen here with me, namely…
CapMan, Webcast, Q3'26
Language: English11/5/2026, 7:30 AM
Charlotte Good morning and welcome to this presentation of CapMan. Q3 2026 interim report. Presenting today we have Pia Kåll, CEO of CapMan. And after the presentation, we will have a Q&A session. You…
Marimekko, Webcast, Q3'26
Language: English11/4/2026, 12:00 PM
Anna Good afternoon. My name is Anna and I am the IRO of Marimekko. It is my pleasure to welcome you to our Q3 webcast. With me, I have our president and CEO, Tiina Alahuhta, who will walk you through…
Administer, Webcast, Q3'26
Language: Finnish11/4/2026, 9:00 AM
Kimmo Herranen Welcome to the Administer Q3 2026 interim report. Results. Meillä on se alkaa. I am Kimmo Herranen. Kalle Lehtonen. Also. Kaarina og. Yelken. Kalle Lehtonen En el coco. Madan. Parannus.…
Kempower, Webcast, Q3'26
Language: English11/4/2026, 8:30 AM
Unknown 1 Powering the planet. Kempower. We charge our planet for the better. By powering the electric movement. We enable quick and scalable EV charging solutions for everyone and everywhere. We ma…